BEVERLY, Mass.--(BUSINESS WIRE)--Jan. 10, 2006--Cell Signaling Technology, Inc. (CST) announced today a second agreement with AstraZeneca under which an expanded pilot study will be performed with CST’s PhosphoScan(TM) technology to identify phosphorylation profiles and prospective biomarkers of kinase targeted lead compounds. CST’s PhosphoScan(TM) proteomics technology is a patent-pending strategy that enables the discovery of drug target phospho-profiles (Phospho-Signatures(TM)) in cells and disease tissues. The PhosphoScan(TM) technology involves immunoaffinity purification and mass spectroscopy and was described in the journal, Nature Biotechnology (Rush J. et al, Nat. Biotechnol. 23, 94-101 (2005)). The Phospho-Signatures(TM) discovered with PhosphoScan(TM) may enable biomarker assays for target validation and therapeutic kinase inhibitor clinical development.
